KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organon (OGN) Total Current Liabilities (2020 - 2025)

Organon (OGN) has 6 years of Total Current Liabilities data on record, last reported at $2.4 billion in Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 12.07% year-over-year to $2.4 billion; the TTM value through Dec 2025 reached $2.4 billion, down 12.07%, while the annual FY2025 figure was $2.4 billion, 12.07% down from the prior year.
  • Total Current Liabilities reached $2.4 billion in Q4 2025 per OGN's latest filing, down from $2.7 billion in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $2.9 billion in Q4 2023 and bottomed at $2.3 billion in Q1 2022.
  • Average Total Current Liabilities over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2021.
  • Peak YoY movement for Total Current Liabilities: fell 19.79% in 2022, then grew 16.16% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $2.6 billion in 2021, then dropped by 3.27% to $2.5 billion in 2022, then grew by 16.16% to $2.9 billion in 2023, then dropped by 6.85% to $2.7 billion in 2024, then dropped by 12.07% to $2.4 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $2.4 billion in Q4 2025, $2.7 billion in Q3 2025, and $2.8 billion in Q2 2025.